Linked Life Data

21370258

Source:http://linkedlifedata.com/resource/pubmed/id/21370258

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2011-4-20
pubmed:abstractText
Levodopa initially provides good symptomatic control of the symptoms of Parkinson's disease, but motor complications often develop after long-term use. Other classes of antiparkinsonian drugs including dopamine agonists, catechol-O-methyl transferase inhibitors, or monoamine oxidase type B inhibitors are then added as adjuvant therapy. It is unclear whether one class of drug is more effective than another. This meta-analysis evaluates the comparative benefits and risks of these agents as adjuvant treatment in Parkinson's disease patients with motor complications.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1531-8257
pubmed:author
pubmed:copyrightInfo
Copyright © 2011 Movement Disorder Society.
pubmed:issnType
Electronic
pubmed:volume
26
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
587-98
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease.
pubmed:affiliation
Birmingham Clinical Trials Unit, College of Medical & Dental Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom. r.l.harrison@bham.ac.uk
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't, Meta-Analysis